Chardan is acting as manager.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SONN:
- Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance
- Sonnet BioTherapeutics regains compliance with Nasdaq
- Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment
- Sonnet BioTherapeutics, Alkem enter licensing agreement for SON-080
- Sonnet BioTherapeutics receives funding through NJEDA, Australia tax programs